Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Jingjing ¹ , LU Jiaju ¹ , SHI Jiang ¹ , LIN Qinglin ² , GUO Hong ² , TIAN Jinhui ³ ,  LIU Jian ² , YANG Kehu ³

1. The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, P.R.China;
2. Department of ICU, The First Hospital of Lanzhou University, Lanzhou, 73000, P.R.China;
3. Evidence-Based Medicine Center of Lanzhou University, Lanzhou, 73000, P.R.China;

Corresponding?author：

LIU Jian, Email: medecinliu@sina.com

Keywords：

Docetaxel; 3D-CRT; Esophagus cancer; Randomized controlled trial; Meta-analysis; Systematic review

DOI：

10.7507/1672-2531.201703088

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo systematically review efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy (3D-CRT) in treatment of esophageal cancer.MethodsDatabases including PubMed, EMbase, The Cochrane Library, Web of Science, CNKI and WanFang Data were searched from inception to February 2017 to collect randomized controlled trials (RCTs) and quasi-randomized control trials (qRCTs) about docetaxel chemotherapy combine with 3D-CRT in treatment of esophageal cancer. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using Stata 12.0 software.ResultsA total of 17 RCTs involving 1 353 patients were included. The results of meta-analysis showed that, compared with the radiotherapy alone, the docetaxel chemotherapy combine with 3D-CRT could improve effective rate (OR=1.25, 95%CI 1.07 to 1.47, P=0.003), 3-year survival rate (OR=1.91, 95%CI 1.19 to 3.06, P=0.006), but there were no significant differences in 1-year survival rate (OR=1.28, 95%CI 0.95 to 1.72, P=0.105), hematologic toxicities (OR=1.13, 95%CI 0.85 to 1.49, P=0.389) and gastrointestinal reactions (OR=1.19, 95%CI 0.90 to 1.57, P=0.181).ConclusionsCompared with radiotherapy alone, docetaxel chemotherapy combine with 3D-CRT can improve the effective rate, 3-year survival rate, but not increase the incidences of adverse effects. Due to limited quantity and quality of the included studies, more high quality studies are needed to verify above conclusion.

Citation： LIU Jingjing, LU Jiaju, SHI Jiang, LIN Qinglin, GUO Hong, TIAN Jinhui, LIU Jian, YANG Kehu. Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review. Chinese Journal of Evidence-Based Medicine, 2017, 17(9): 1029-1036. doi: 10.7507/1672-2531.201703088 Copy

1.	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
2.	Mocanu A, Barla R, Hoara P, et al. Current endoscopic methods of radical therapy in early esophageal cancer. J Med Life, 2015, 8(2): 150-156.
3.	Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol, 2012, 70(5): 683-690.
4.	Fulton B, Spencer CM. Docetaxel. Drugs, 1996, 51(6): 1075-1092.
5.	Yamaguchi S, Ohguri T, Imada H, et al. Multimodal approaches including three-dimensional conformal reirradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res, 2011, 52(52): 812-820.
6.	Wang RH. Froreflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol, 2015, 21(17): 5210-5219.
7.	Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Available at: http://handbook. cochrane.org.
8.	譚新勁, 劉晉湘, 任麗, 等. 低劑量每周一次多西他賽同步放療治療食管癌的臨床療效. 實用癌癥雜志, 2009, 24(4): 388-390.
9.	王華. 多西他賽化療聯合放療治療食管癌的療效分析. 吉林醫學, 2016, 37(9): 2273-2274.
10.	宋利. 多西他賽化療聯合放療治療食管癌的療效分析. 中國衛生標準管理, 2016, 7(22): 97-99.
11.	張越棟. 多西他賽化療聯合放療治療食管癌療效的臨床分析. 中國實用醫藥, 2015, 10(13): 209-210.
12.	張建輝. 多西他賽化療聯合放療治療食管癌療效的臨床分析. 基層醫學論壇, 2016, 20(6): 730-731.
13.	臧曄. 多西他賽化療聯合放療治療食管癌臨床療效分析. 亞太傳統醫藥, 2014, 10(7): 124-126.
14.	王青民, 楊敬磊, 張玉萍. 放療聯合多西他賽治療中晚期食管癌療效觀察. 腫瘤基礎與臨床, 2013, 26(2): 116-118.
15.	李佳, 戴鵬, 蔣曉東. 多西他賽與調強適形放療同步治療食管癌臨床療效觀察. 齊齊哈爾醫學院學報, 2011, 32(1): 24-25.
16.	胡筱, 馬桂香, 蔣文慧, 等. 同步放化療與單純放療對局部晚期食管癌療效的對比分析. 中國腫瘤外科雜志, 2015, 7(3): 189-191.
17.	丁華, 蔡晶, 謝國棟, 等. 三維適形放療聯合多西他賽同步化療治療中晚期食管癌的臨床研究. 齊齊哈爾醫學院學報, 2010, 31(22): 3546-3547.
18.	熊慧如, 尤傳文, 陸錫燕, 等. 多西他賽每周方案聯合放療治療老年局部晚期食管癌的臨床療效觀察. 海南醫學, 2013, 24(6): 793-795.
19.	苑仁冰, 徐麗杰, 黃樹峰, 等. 多西紫杉醇聯合三維適形放療治療食管癌的臨床療效觀察. 中國傷殘醫學, 2012, 20(6): 88-89.
20.	姜麗華. 周劑量多西他賽同步放療治療食管癌. 腫瘤基礎與臨床, 2014, 27(4): 306-307.
21.	谷凡. 探討多西他賽化療聯合放療治療食管癌的臨床療效. 中國實用醫藥, 2015, 10(21): 161-162.
22.	楊常建, 董海林, 聶改紅, 等. 多西他賽化療聯合放療治療食管癌療效的系統評價. 世界臨床醫學, 2016, 10(4): 3-4.
23.	蔣曉東, 于金明, 吳瑾, 等. 多西他賽乏氧增敏放射治療食管癌的臨床研究. 實用腫瘤雜志, 2010, 25(4): 436-440, 441.
24.	郭軍輝. 多西他賽化療聯合放療治療食管癌療效的系統評價. 中國保健營養, 2015, 25(9): 275-276.
25.	Bedford JL, Viviers L, Guzel Z, et al. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Ra-diother Oncol, 2000, 57(2): 183-193.
26.	Kim DE, Kim UJ, Choi WY, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat, 2013, 45(4): 276-284.
27.	Pasini F, de Manzoni G, Durante E, et al. High pathological response rate in esophageal cancer after neoadjuvant radiotherapy (RT) and concomitant weekly chemotherapy with dose escalating of docetaxel. J Clin Oncol, 2004, 22(14 suppl): 4059.
28.	Feiran L, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol, 2013(8): 1558-1562.
29.	Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer, 2000, 36(13): 1649-1660.
30.	Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies. Cancer Radiother, 2004, 8(suppl 1): S95-105.
31.	Hertel H, Kohler C, Michels W, et al. Laparoscopic-assited radical vaginal hysterectomy(LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol, 2003, 90(3): 505-511.

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
2. Mocanu A, Barla R, Hoara P, et al. Current endoscopic methods of radical therapy in early esophageal cancer. J Med Life, 2015, 8(2): 150-156.
3. Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol, 2012, 70(5): 683-690.
4. Fulton B, Spencer CM. Docetaxel. Drugs, 1996, 51(6): 1075-1092.
5. Yamaguchi S, Ohguri T, Imada H, et al. Multimodal approaches including three-dimensional conformal reirradiation for recurrent or persistent esophageal cancer: preliminary results. J Radiat Res, 2011, 52(52): 812-820.
6. Wang RH. Froreflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol, 2015, 21(17): 5210-5219.
7. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Available at: http://handbook. cochrane.org.
8. 譚新勁, 劉晉湘, 任麗, 等. 低劑量每周一次多西他賽同步放療治療食管癌的臨床療效. 實用癌癥雜志, 2009, 24(4): 388-390.
9. 王華. 多西他賽化療聯合放療治療食管癌的療效分析. 吉林醫學, 2016, 37(9): 2273-2274.
10. 宋利. 多西他賽化療聯合放療治療食管癌的療效分析. 中國衛生標準管理, 2016, 7(22): 97-99.
11. 張越棟. 多西他賽化療聯合放療治療食管癌療效的臨床分析. 中國實用醫藥, 2015, 10(13): 209-210.
12. 張建輝. 多西他賽化療聯合放療治療食管癌療效的臨床分析. 基層醫學論壇, 2016, 20(6): 730-731.
13. 臧曄. 多西他賽化療聯合放療治療食管癌臨床療效分析. 亞太傳統醫藥, 2014, 10(7): 124-126.
14. 王青民, 楊敬磊, 張玉萍. 放療聯合多西他賽治療中晚期食管癌療效觀察. 腫瘤基礎與臨床, 2013, 26(2): 116-118.
15. 李佳, 戴鵬, 蔣曉東. 多西他賽與調強適形放療同步治療食管癌臨床療效觀察. 齊齊哈爾醫學院學報, 2011, 32(1): 24-25.
16. 胡筱, 馬桂香, 蔣文慧, 等. 同步放化療與單純放療對局部晚期食管癌療效的對比分析. 中國腫瘤外科雜志, 2015, 7(3): 189-191.
17. 丁華, 蔡晶, 謝國棟, 等. 三維適形放療聯合多西他賽同步化療治療中晚期食管癌的臨床研究. 齊齊哈爾醫學院學報, 2010, 31(22): 3546-3547.
18. 熊慧如, 尤傳文, 陸錫燕, 等. 多西他賽每周方案聯合放療治療老年局部晚期食管癌的臨床療效觀察. 海南醫學, 2013, 24(6): 793-795.
19. 苑仁冰, 徐麗杰, 黃樹峰, 等. 多西紫杉醇聯合三維適形放療治療食管癌的臨床療效觀察. 中國傷殘醫學, 2012, 20(6): 88-89.
20. 姜麗華. 周劑量多西他賽同步放療治療食管癌. 腫瘤基礎與臨床, 2014, 27(4): 306-307.
21. 谷凡. 探討多西他賽化療聯合放療治療食管癌的臨床療效. 中國實用醫藥, 2015, 10(21): 161-162.
22. 楊常建, 董海林, 聶改紅, 等. 多西他賽化療聯合放療治療食管癌療效的系統評價. 世界臨床醫學, 2016, 10(4): 3-4.
23. 蔣曉東, 于金明, 吳瑾, 等. 多西他賽乏氧增敏放射治療食管癌的臨床研究. 實用腫瘤雜志, 2010, 25(4): 436-440, 441.
24. 郭軍輝. 多西他賽化療聯合放療治療食管癌療效的系統評價. 中國保健營養, 2015, 25(9): 275-276.
25. Bedford JL, Viviers L, Guzel Z, et al. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Ra-diother Oncol, 2000, 57(2): 183-193.
26. Kim DE, Kim UJ, Choi WY, et al. Clinical prognostic factors for locally advanced esophageal squamous carcinoma treated after definitive chemoradiotherapy. Cancer Res Treat, 2013, 45(4): 276-284.
27. Pasini F, de Manzoni G, Durante E, et al. High pathological response rate in esophageal cancer after neoadjuvant radiotherapy (RT) and concomitant weekly chemotherapy with dose escalating of docetaxel. J Clin Oncol, 2004, 22(14 suppl): 4059.
28. Feiran L, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol, 2013(8): 1558-1562.
29. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer, 2000, 36(13): 1649-1660.
30. Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies. Cancer Radiother, 2004, 8(suppl 1): S95-105.
31. Hertel H, Kohler C, Michels W, et al. Laparoscopic-assited radical vaginal hysterectomy(LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol, 2003, 90(3): 505-511.

Previous Article
Correlation of pSTAT3 overexpression and prognosis in lung cancer patients: a meta-analysis
Next Article
Influence of doula delivery on postpartum depression in puerperae: a meta-analysis

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of docetaxel chemotherapy combine with 3-dimensional conformal radiation therapy in treatment of esophageal cancer: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content